The U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for Imfinzi (durvalumab) for the treatment of certain non-small cell lung cancer (NSCLC) and bladder cancer patients. Granted under priority review, the approval allows Imfinzi to be administered at a fixed dose of 1,500 mg every four weeks for patients weighing more than 30 kg (about 66 pounds). It is an alternative to the weight-based dosing of 10 mg/kg every two weeks previously set for these…
You must be logged in to read/download the full post.
The post FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancer appeared first on BioNewsFeeds.